Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
5 reports, 3 independent
Updated Sep 23
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA committee voted on Grail's premarket approval.1 source
S&P Global reported on Grail's stock performance as the company continues NHS trials and seeks FDA approval.1 source
Grail advances its Galleri test through NHS trials, FDA approval seeks, and ASCO presentation.1 source